BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series

Published:2020-11-09 Issue:6 Volume:50 Page:1257-1262
ISSN:0364-2348
Container-title:Skeletal Radiology
language:en
Short-container-title:Skeletal Radiol

Author:

Bartlett David J.,Erie Andrew J.,Baffour Francis I.,Broski Stephen M.,Glazebrook Katrina N.

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s00256-020-03665-9.pdf

Reference19 articles.

1. Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(10):2581–7.

2. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.

3. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.

4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

5. Choy B, Chou S, Anforth R, Fernández-Peñas P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493–7.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lobular panniculitis and diffuse osteonecrosis occurring during anti‐MEK and anti‐BRAF combination therapy for metastatic melanoma;Journal of the European Academy of Dermatology and Venereology;2023-04-05

2. Panniculitis does not predict clinical response in patients with advanced melanoma under targeted therapy;European Journal of Dermatology;2023-04

3. Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy;Journal of Cutaneous Pathology;2021-10-21

4. Dabrafenib/trametinib/vemurafenib;Reactions Weekly;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3